Seladelpar, sold under the brand name Livdelzi, is a medication used for the treatment of primary biliary cholangitis.

[4] Seladelpar was approved for medical use in the United States in August 2024.

[1] Clinically, seladelpar reduces pruritus (itching) and interleukin-31 in people with primary biliary cholangitis.

[9] In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Seladelpar Gilead, intended for the treatment of primary biliary cholangitis.

[10] The applicant for this medicinal product is Gilead Sciences Ireland UC.